Kommentar
When Cost-Effectiveness Crosses Borders—Nirsevimab as an Example
JAMA Pediatrics · 01.07.2026 · 180 (7) · 726
DOI: 10.1001/jamapediatrics.2026.0823 ↗Kurz gefasst
Kommentar in der Zeitschrift JAMA Pediatrics, erschienen am 01.07.2026. Verfasst von Lisa A Prosser und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan School of Public Health, Ann Arbor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- University of Michigan School of Public Health, Ann Arbor.
- University of Michigan Medical School, Ann Arbor.
Zitieren
APA
Prosser, L. A., & Hutton, D. W. (2026). When Cost-Effectiveness Crosses Borders—Nirsevimab as an Example. JAMA Pediatrics, 180(7), 726. https://doi.org/10.1001/jamapediatrics.2026.0823
Vancouver
Prosser LA, Hutton DW. When Cost-Effectiveness Crosses Borders—Nirsevimab as an Example. JAMA Pediatrics. 2026;180(7):726. doi:10.1001/jamapediatrics.2026.0823
BibTeX
@article{Prosser2026,
author = {Prosser, Lisa A and Hutton, David W},
title = {When Cost-Effectiveness Crosses Borders—Nirsevimab as an Example},
journal = {JAMA Pediatrics},
year = {2026},
volume = {180},
number = {7},
pages = {726},
doi = {10.1001/jamapediatrics.2026.0823}
}
EUVIMED